# Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

> **NCT04857619** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 763 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **OTHER:** None (Observational study)

## Key facts

- **NCT ID:** NCT04857619
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-14
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 763 (ACTUAL)
- **Last updated:** 2024-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857619, "Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04857619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*